GlassScriptPhysician profile
Fahim Qureshi
NPI 1093785297
$5,870.75
in general payments reported to CMS, 2019-2025
21 companies · $2,622 in 2025
The $2,622 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $236 · 2021: $31.00 · 2022: $179 · 2023: $631 · 2024: $1,122 · 2025: $2,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,209 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,208.83 |
| Education | $166.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $957.41 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $692.89 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $630.68 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $594.63 | 2022-2025 | Caplyta |
| Alkermes, INC. | $453.22 | 2023-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $385.49 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $367.02 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $287.66 | 2019-2025 | Ingrezza |
| Abbvie INC. | $257.21 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $219.67 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.29 | 2019-2025 | Trintellix |
| Corium, LLC | $162.62 | 2023-2025 | Azstarys |
| Allergan, INC. | $150.68 | 2019 | |
| Almatica Pharma LLC | $150.32 | 2024-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $117.75 | 2025 | Spravato |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $68.82 | 2019-2020 | |
| Shire North American Group INC | $64.17 | 2019 | |
| Arbor Pharmaceuticals, INC. | $44.67 | 2019-2020 | |
| Adlon Therapeutics L.P. | $23.22 | 2019 | |
| Idorsia Pharmaceuticals US INC | $22.59 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $14.74 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahim Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.